Louvain-la-Neuve, Belgium – September 5th, 2024 – The Minafin Group, a leading developer and producer of fine chemicals, today announced the appointment of Olivier Ubrich as CEO of its Health … Learn More
Louvain-la-Neuve, June 19th, 2024 – Vinorelbine is an important drug substance used to treat breast and lung cancers. Minakem is the sole API manufacturer located in Europe. This molecule remains … Learn More
Minakem’s investment in a new production unit in Lassalle, Montreal, for corticosteroid APIs reflects the company’s recognition of the importance and growing demand for these active pharmaceutical ingredients (API). The … Learn More
Montreal, April 8th, 2024 – The COVID-19 pandemic has prompted North America and Europe to reconsider the feasibility of slightly rebalancing their supply chains, which currently heavily rely on Asia. … Learn More
Minakem Small Molceules API list Jan24
Minafin has strengthened the industrial and commercial base of its Healthcare Chemicals division with the acquisition of Delmar in Montreal, Canada, in July 2023. This operation enables Minakem to establish … Learn More
EcoVadis Rating validates Minakem’s business sustainability commitments and performance Minakem announced today that it has achieved a Gold Medal from EcoVadis, the worlds’ most trusted provider of business sustainability ratings. … Learn More
Reach Separations and Minakem have decided to establish a collaboration to offer the full range of service to purify your molecules by HPLC to their customers to reduce time-to-market. Reach … Learn More
L‘arrivée de Sébastien Poncet à la tête du centre de profit Minakem Génériques permettra de valoriser le potentiel de croissance de son portefeuille de procédés originaux et de saisir les … Learn More
Sébastien Poncet is charged with enhancing the portfolio of proprietary processes and seizing opportunities in new therapies Louvain-la-Neuve, January 27, 2022 – The Health Chemistry division of the Minafin Group today welcomes Sébastien Poncet as managing director of the Minakem Generics and New Therapies business unit. He is also an executive … Learn More